ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additio...
July 21 2020 - 4:05PM
ALX Oncology Holdings Inc., (Nasdaq: ALXO) a clinical-stage
immuno-oncology company developing therapies that block the CD47
checkpoint pathway, today announced the closing of its initial
public offering of 9,775,000 shares of common stock, including the
full exercise of the underwriters’ option to purchase up to
1,275,000 additional shares of common stock, at a public offering
price of $19.00 per share. The aggregate gross proceeds to ALX
Oncology from the offering were approximately $185.7 million,
before deducting underwriting discounts and commissions and other
offering expenses. All of the shares in the offering were offered
by ALX Oncology.
ALX Oncology’s common stock began trading on The Nasdaq Global
Select Market on July 17, 2020 under the ticker symbol "ALXO."
Jefferies, Credit Suisse, Piper Sandler and Cantor acted as
joint book-running managers for the offering. LifeSci Capital acted
as lead manager for the offering.
Registration statements relating to these
securities have been filed with the Securities and Exchange
Commission and became effective on July 16, 2020. The
offering was made only by means of a prospectus. Copies of the
final prospectus relating to this offering may be obtained from
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at
(877) 821-7388, or by email
at prospectus_department@Jefferies.com; Credit Suisse
Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis
Stephens Drive, Morrisville, NC 27560, by telephone at (800)
221-1037, or by email at usa.prospectus@credit-suisse.com;
Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet
Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800)
747-3924, or by email at prospectus@psc.com; or Cantor
Fitzgerald & Co., Attention: Capital Markets, 499 Park
Avenue, 6th Floor New York, New York 10022, or by email
at prospectus@cantor.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About ALX Oncology
ALX Oncology is a clinical-stage immuno-oncology company focused
on helping patients fight cancer by developing therapies that block
the CD47 checkpoint pathway and bridge the innate and adaptive
immune system. ALX Oncology’s lead product candidate, ALX148, is a
next generation CD47 blocking therapeutic that combines a
high-affinity CD47 binding domain with an inactivated, proprietary
Fc domain. ALX148 has demonstrated promising clinical responses
across a range of hematologic and solid malignancies in combination
with a number of leading anti-cancer agents. ALX Oncology intends
to advance ALX148 into clinical development for the treatment of
myelodysplastic syndromes and to continue clinical development for
the treatment of a range of solid tumor indications.
Media Contact
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
Investor Contact
Peter Garcia
CFO, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Aug 2024 to Sep 2024
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Sep 2023 to Sep 2024